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The recently identified myokine irisin conveys some of the benefits of exercise. Hypopituita-
rism with adult growth hormone deficiency (HP) is a situation characterized by decreased
GH secretion and an altered body composition.
Objective
Our aim was to study the skeletal muscle hormone irisin in HP, and compare the results
with a similar group of normal subjects.
Participants and Methods
Seventeen HP patients and fifty-one normal subjects of similar age and sex were studied.
The diagnosis of GH deficiency was confirmed by the presence of pituitary disease and a
peak GH secretion below 3 μg/L after an insulin tolerance test. The patients were ade-
quately treated for all pituitary hormone deficits, except for GH. Fasting serum irisin was
measured with an enzyme immunoassay, and HOMA-IR, QUICKI and HOMA-β were
calculated.
Results
Fasting irisin levels (ng/ml) were similar in normal [208.42 (168.44–249.23)] and HP patients
[195.13 (178.44–241.44)]. In the control group there were moderate significant positive cor-
relations between irisin and BMI, waist circumference, leptin, fasting insulin, HOMA-IR,
HOMA-β, triglycerides, and cholesterol. In the control group there were moderate significant
negative correlations between irisin and IGF-I and QUICKI. In the hypopituitary group there
were moderate significant positive correlations between irisin and body fat and HOMA-β.
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Conclusions
We found similar irisin levels in GH deficiency hypopituitary patients when compared with
normal subjects. The correlation between irisin and adiposity related factors suggests that
that in the case of this clinical model, irisin is regulated by adiposity and not by GH.
Introduction
Exercise has beneficial effects on systemic metabolism. Fibronectin type III domain-containing
type 5 (FNDC5), a type I transmembrane protein, and its circulating form, irisin, conveys some
of these benefits in mice [1]. Irisin acts on white adipose cells in culture and in vivo to stimulate
uncoupling protein 1 (UCP1) expression and a broad program of brown-fat-like development.
Irisin is induced with exercise in mice and humans, and mildly increased irisin levels in the
blood cause an increase in energy expenditure in mice, with no changes in movement or food
intake [1].
Lean body mass has been found to be the main determining factor for circulating irisin [2].
As in mice, the FNDC5 gene is expressed in human muscle. Age and muscle mass are the pri-
mary predictors for circulating irisin, with young male athletes having several-fold higher irisin
levels than obese middle-aged women [3]. Circulating irisin levels increase in response to acute
exercise, whereas muscle FNDC5 mRNA and circulating irisin levels decrease after surgically
induced weight loss in parallel to a decrease in body mass [3]. In contrast, no differences in cir-
culating irisin levels have been found in individuals with sarcopenia compared to control sub-
jects, and were not correlated with the skeletal muscle mass index [4]. Irisin plasma levels have
been found to be significantly correlated with high levels of direct and indirect adiposity mark-
ers, such as weight, body mass index (BMI), waist circumference, and fat mass, as measured by
bioimpedance [5]. Irisin strongly reflects body fat mass, suggesting that circulating irisin levels
are conditioned by adiposity levels [6]. Circulating irisin is positively linked to BMI and leptin
in school-age children, supporting the notion that irisin is produced by adipose tissue. [7]
Hypopituitarism with growth hormone deficiency (HP) is a clinical situation characterized
by decreased GH secretion. In most studies on patients with GH deficiency there is an altered
body composition, with decreased lean body mass, which improves with GH treatment [8] [9].
In adults with GH deficiency, lean body mass increased in GH-treated subjects and fat mass
was reduced. Changes in lean body mass and fat mass were dose-related [10]. Fifteen-year GH
replacement in GH-deficient adults induced a transient decrease in body fat, and sustained
improvements of lean soft tissue [9]. In addition to the differences in GH secretion, and taking
into account these theoretical differences in body composition in hypopituitary patients, the
study of circulating irisin is of major interest in this group of patients. Moreover, recent data
suggest a relationship between the GH/IGF-I axis and irisin [11]. Irisin has the potential to be a
clinical biomarker of sarcopenia or adiposity in hypopituitarism.
Our aim was to study the skeletal muscle hormone irisin in HP, and to compare the results
with a similar group of control subjects.
Subjects and Methods
Subjects
All the studies were conducted in accordance with the Declaration of Helsinki. The study pro-
tocol was approved by our centre´s ethics committee (Hospital A Coruña, Xunta de Galicia),
Irisin in Hypopituitarism
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and written informed consent was obtained from all patients and controls. We included a total
of sixty-eight patients and controls in our study. Seventeen HP patients (ten women) were
studied. The diagnosis of adult GHD was confirmed by the presence of pituitary disease and a
peak GH secretion below 3 μg/L after an insulin tolerance test, at least 12 months prior to the
study. The patients were adequately treated for all pituitary hormone deficits, except for GH.
The patients were on stable hormone replacement therapy for pituitary hormone deficits in the
form of levothyroxine, hydrocortisone, desmopressin, and sex steroids for at least 3 months
before joining the study. The adequacy of hormone replacement was assessed at the beginning
of the study. None of the patients received GH therapy within 12 months prior to entering the
study. The diagnoses of the patient´s pituitary diseases were nonfunctioning pituitary adenoma
(n = 6), craniopharyngioma (n = 7), traumatic brain injury (n = 1), nasopharyngeal carcinoma
with previous cranial radiotherapy (n = 1) idiopathic empty sella (n = 1), and hypothalamic
sarcoidosis (n = 1). As a control group, we studied fifty-one healthy subjects (thirty women),
selected from a pool of volunteers available to our unit in a 3:1 ratio. None of the controls had
diabetes mellitus or other medical problems, nor were they taking any drugs. The subjects had
been eating a weight-maintenance diet and doing their usual exercise routines for at least two
weeks prior to the study.
Study procedure
Between 08.30 and 09.00 a.m., following an overnight fasting and while seated, a peripheral
venous line was obtained. Fifteen minutes later we obtained blood samples for irisin, glucose,
cholesterol, triglycerides, c-reactive protein, insulin, GH, leptin, and insulin-like growth factor
1(IGF-1). All blood samples were immediately centrifuged, separated and frozen at -80°C.
Mid-waist circumference was measured as the midpoint between the iliac crest and the lowest
rib, with the patient in the upright position. Total body fat was calculated through bioelectrical
impedance analysis (BIA).
Assays and other methods
All blood samples were immediately differentially centrifuged, and the serum samples obtained
were collected and stored at -80 C. Serum irisin was measured with enzyme immunoassay
(EIA) kits (Phoenix Pharmaceuticals, Karlsruhe, Germany). The sensitivity of the assay was 6.6
ng/mL and the intra-assay CV was 4%–6%. Serum GH (μg/L) was measured by a solid-phase,
two-site chemiluminescent enzyme immunometric assay (Immulite, EURO/DPC, Los Angeles,
CA, USA) with a sensitivity of 0.01 μg/L and with intra-assay coefficients of variation of 5.3%,
6.0% and 6.5% for low, medium and high serum GH levels respectively; and with inter-assay
coefficients of variation of 6.5%, 5.5% and 6.6% for low, medium and high serum GH levels
respectively. IGF-1 (ng/mL) was determined by a chemiluminescence assay (Nichols Institute,
San Clemente, CA, USA) and with intra-assay coefficients of variation of 4.8%, 5.2% and 4.4%
for low, medium and high serum IGF-1 levels respectively; and with interassay coefficients of
variation of 7.7%, 7.4% and 4.7% for low, medium and high serum IGF-I levels respectively.
Insulin (μU/mL) was measured with a solid-phase two-site chemiluminescent immunometric
assay (Immulite 2000 Insulin, DPC, Los Angeles, CA, USA) and with intra-assay coefficients of
variation of 5.5%, 3.3% and 3.7% for low, medium and high serum insulin levels respectively;
and with inter-assay coefficients of variation of 7.3%, 4.1% and 5.3% for low, medium and high
serum insulin levels respectively. Leptin (ng/mL) was measured by radioimmunoassay (Med-
iagnost, Tubigen, Germany) and with intra-assay and inter-assay coefficients of variation of
5.3% and 13.6% respectively. Serum glucose (mg/dL) was measured with an automatic glucose
oxidase method (Roche Diagnostics, Mannheim, Germany). Serum c-reactive protein, serum
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triglycerides, serum total cholesterol, serum HDL-cholesterol and serum LDL-cholesterol were
measured using the ADVIA Chemistry XPT System (Global Siemens Headquarters, Munich,
Germany).All the samples from a given subject were analyzed in the same assay run.
Calculations
Insulin sensitivity (IS) was measured with the following methods: HOMA-IR with the formula:
fasting insulin (μU/mL) x fasting glucose (mmol/L)/22.5; quantitative IS check index
(QUICKI) with the formula: 1/[log insulin(μU/mL) + log glucose (mg/dL). For HOMA-IR,
lower values indicate higher IS; for QUICKI higher values indicate higher IS [12, 13].
Insulin secretion was estimated using the basal insulin values by the HOMA-β: [20 x fasting
insulin (μU/mL)]/[fasting glucose (mmol/L)– 3.5].
Statistical analysis
Quantitative variables were expressed as median and interquartile range. Due to the small sam-
ple size in one of the groups, the non-parametric Mann-Whitney test was used to compare
hypopituitary and control subjects with respect to biochemical data, hormonal records and
insulin secretion and action indices.
The association between irisin and age, gender, BMI, body fat, waist circumference, fasting
glucose, fasting insulin, HOMA-IR HOMA-β, QUICKI, GH, IGF-I, leptin, cholesterol, triglyc-
erides and c-reactive protein was analyzed using Spearman’s Rho correlation coefficient. The
linearity of associations with irisin was also explored by means of penalized cubic regression
splines.
In the multivariate analysis, both linear regression and generalized additive (GAM) models
were used to investigate the variables associated with irisin. Mathematically, some covariates in
GAMmodels can be replaced by arbitrary smooth functions, so finally they were fitted to allow
for the nonlinear effects detected in some of the variables studied. Since departures from linear-
ity were not observed for any of the analyzed variables, only the final multivariate linear regres-
sion model is shown in the results section.
Statistical analysis was carried out using the R 2.15.1 software (R Foundation for Statistical
Computing, Vienna, Austria) and the Statistical Package for Social Sciences version 19.0 for
Windows (IBM, Armonk, NY, USA). All statistical tests were two-sided. Only p-values<0.05
were considered statistically significant.
Results
The age and adiposity indices of the healthy control group and HP patients are shown in
Table 1. There was no significant difference in the parameters studied between the two groups.
Table 1. Age, BMI, waist and total body fat (median, interquartile ranges) in hypopituitary patients and
control subjects.
Control subjects (n = 51) Hypopituitary patients (n = 17)
Median (interquartile ranges) Median (interquartile ranges)
Age (years) 36.00 (30.00–50.00) 39.00 (35.00–46.00)
BMI (kg/m2) 27.70 (23.40–31.80) 25.20 (23.00–30.10)
Waist (cm) 92.00 (85.00–104.00) 98.00 (90.00–114.00)
Body fat (%) 30.00 (24.80–38.20) 27.70 (23.90–36.70)
doi:10.1371/journal.pone.0160364.t001
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Fasting serum levels
Fasting Irisin, fasting glucose, hormones, lipids and c-reactive protein results are shown in
Table 2.
Fasting Irisin levels were similar in healthy control and hypopituitary patients. Fasting GH
levels were lower in the HP group than in healthy controls; 0.08 (0.05–0.20) vs 0.20 (0.06–1.69)
for the HP and control group, respectively, p<0.05. Fasting IGF-I levels were lower in the HP
group than in healthy controls; 79.00 (60.00–92.00) vs 139.00 (108.00–175.00) for the HP and
control group, respectively, p<0.05. Fasting cortisol levels were lower in the hypopituitary
group than in healthy controls; 2.20 (1.30–5.10) vs 18.00 (15.30–20.70) for the HP and control
group, respectively, p<0.05. Fasting total cholesterol (p<0.05) and c-reactive protein (p<0.05)
were higher in the HP group than in healthy controls.
Insulin secretion and action indices
QUICKI, HOMA-IR and HOMA- β as estimative of insulin action and β cell function (median
and interquartile range) are shown in Table 2. QUICKI and HOMA-IR levels were similar in
the healthy control and hypopituitary patients. HOMA-β was similar in healthy control and
hypopituitary patients.
Correlations
In the control group there were moderate significant positive correlations between irisin and
BMI, waist circumference, leptin, fasting insulin, HOMA-IR, HOMA-β, triglycerides and cho-
lesterol. In the control group, there were moderate significant negative correlations between iri-
sin and IGF-I and QUICKI. In the hypopituitary group, there were moderate significant
positive correlations between irisin and body fat and HOMA-β (Table 3).
There were significant moderate correlations between irisin and BMI, body fat, waist cir-
cumference, fasting insulin, HOMA-IR HOMA-β, QUICKI, leptin, cholesterol and
Table 2. Biochemical and Hormonal data (median, interquartile ranges) in hypopituitary patients and control subjects.
Control subjects (n = 51) Hypopituitary patients (n = 17)
Median (interquartile ranges) Median (interquartile ranges)
Irisin (ng/ml) 208.42 (168.44–249.23) 195.13 (178.44–241.44)
Fasting Glucose (mg/dl) 95.00 (89.00–100.00) 92.00 (81.00–103.00)
Fasting Insulin (μUI/ml) 6.60 (2.14–11.50) 8.20 (2.00–15.60)
GH (μg/l) 0.20* (0.06–1.69) 0.08 (0.05–0.20)
Cortisol (μg/dl) 18.00* (15.30–20.70) 2.20 (1.30–5.10)
IGF-1(ng/ml) 139.00* (108.00–175.00) 79.00 (60.00–92.00)
Leptin (ng/ml) 23.20 (11.50–38.70) 11.90 (6.00–18.70)
Triglycerides (mg/dl) 89.00 (66.00–121.00) 96.00 (64.00–126.00)
Total Cholesterol (mg/dl) 187.00* (170.00–226.00) 215.00 (198.00–227.00)
LDL cholesterol (mg/dl) 105.60 (93.40–138.00) 134.00 (120.00–149.00)
HDL cholesterol (mg/dl) 54.00 (46.00–63.00) 54.00 (46.00–59.00)
C-Reactive Protein (mg/dl) 0.26* (0.18–0.48) 0.55 (0.30–1.02)
QUICKI 0.36 (0.32–0.43) 0.34 (0.31–0.44)
HOMA-IR 1.55 (0.56–2.95) 1.96 (0.48–3.97)
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triglycerides, in the entire group of healthy controls and HP patients (Table 3). These higher
number data have been included for informative purposes only, as correlations including both
cohorts grouped together lead to inaccuracies.
The linearity of associations with irisin was further explored by means of penalized regres-
sion splines (Fig 1).
Due to the significant correlations between the adiposity indices, QUICKI, HOMA-IR,
HOMA- β and irisin, multivariate analysis was used with both linear regression and multivari-
ate linear regression models in order to quantitatively assess the individual contribution of
each predictive measure in explaining the variability between irisin values while in the presence
of the remaining predictors.
After adjusting for BMI, HOMA-IR, fasting GH, leptin, cholesterol and triglycerides, only
triglycerides continued to be a significant predictor for irisin (Table 4).
Discussion
The main results of this study were that fasting irisin levels were found to be similar in normal
and HP patients. In the control group, there were moderate significant positive correlations
between irisin and BMI, waist circumference, leptin, fasting insulin, HOMA-IR, HOMA-β, tri-
glycerides and cholesterol. In the control group, there were moderate significant negative cor-
relations between irisin and IGF-I and QUICKI. In the hypopituitary group, there were
moderate significant positive correlations between irisin and body fat and HOMA-β.
Irisin is a 112 aminoacid cleavage product, formed when FNDC 5 is degraded by proteases
[1]. It was initially characterized as a myokine, thought to be synthesized and released essen-
tially by the skeletal muscle and the myocardium; however, recent studies have indicated that
Table 3. Correlations between irisin and the different adiposity indices and hormonal data in the entire group of healthy controls and hypopituitary
patients, and in the two individual groups.
Irisin (ng/ml)
Control/ Hypopituitary Control Hypopituitary
Rho p Rho Rho
Age 0.111 0.356 0.154 -0.406
BMI 0.404 < 0.001 0.412* 0.113
Waist 0.311 0.008 0.350* 0.122
Body fat (%) 0.343 0.003 0.236 0.537*
Glucose 0.141 0.240 0.126 -0.055
Insulin 0.408 < 0.001 0.399* 0.448
GH (μg/l) -0.027 0.825 -0.107 0.074
Cortisol (μg/dl) 0.074 0.542 0.074 -0.005
IGF-1(ng/ml) -0.163 0.176 -0.331* 0.083
Leptin (ng/ml) 0.339 0.004 0.300* 0.369
Triglycerides (mg/dl) 0.459 < 0.001 0.558* 0.255
Cholesterol (mg/dl) 0.255 0.032 0.349* 0.158
LDL cholesterol (mg/dl) 0.129 0.285 0.138 0.162
HDL cholesterol (mg/dl) -0.162 0.177 -0.183 -0.141
QUICKI -0.415 < 0.001 -0.422* -0.402
HOMA-IR 0.415 < 0.001 0.422* 0.402
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fat [14] [15] and, to a variable extent, several other peripheral tissues [16] may also secrete this
factor. Irisin maintains a remarkable molecular homology across different mammalian species
[17].
The mechanisms that regulate irisin synthesis and secretion are not fully understood. Initial
suggestions that physical exercise and training could stimulate irisin synthesis and secretion
have been supported by the majority of, but not all, later research [16]. Both heat and cold have
also been claimed to stimulate irisin release. Serum irisin levels appear to be elevated in obese
patients, maintaining a direct correlation with fat mass and body mass index [18], although
these associations have not been observed in other studies [16]. It has been posited that irisin
levels could be elevated in obese patients as a compensatory mechanism to progressive fat accu-
mulation [18], and also that this hormone could partly mediate the improvement of glucose
metabolism observed after weight reduction in obese patients with metabolic syndrome [19].
Relatively low serum irisin levels have been reported in type 2 diabetes [20] [21] and fatty liver
disease [18].
This study has revealed a moderate significant positive correlation between Irisin and fast-
ing insulin and HOMA-β. Moreover, there was a moderate significant correlation between Iri-
sin and insulin action indices, such as QUICKI and HOMA -IR. Similar results have been
found in other studies, although not in all populations. Serum irisin has been found to be
higher and related to insulin in acanthosis nigricans-related obesity [22]. In children, in a mul-
tiple linear regression analysis, baseline irisin was significantly associated with HOMA-IR [23].
In women with polycystic ovary syndrome, circulating irisin levels correlated with the area
under the curve of insulin secretion and HOMA-IR [24]. In non-diabetic adult subjects, irisin
levels were positively correlated with fasting and 2 h post-load insulin levels [25]. In patients
with anorexia nervosa and varying stages of obesity, Irisin was positively correlated with BMI,
fat mass, body cell mass, fat free mass and insulin levels [26]. In this study, after carrying out a
multivariate analysis, only triglycerides continued to be a significant predictor for fasting irisin.
Baseline irisin levels have been found to be higher in subjects with metabolic syndrome com-
pared to subjects without metabolic syndrome[27]. In that study, irisin was associated posi-
tively with HOMA-IR and triglycerides [27]. In sedentary subjects, irisin levels have been
found positively associated with metabolic risk factors including triglycerides [28]. In marked
contrast, in obese Chinese adults, stepwise multivariable linear regression analysis showed that
fasting insulin was negatively associated with the serum irisin level [29]. The results of our
study are in line with those of most of the previous studies, and suggest that circulating fasting
irisin is highly dependent on direct and indirect insulin secretion and action indices in control
subjects.
Table 4. Multivariate analysis of variables related to Irisin values: linear regression model.
Irisin (ng/ml))
B SE p 95%CI
BMI 1.725 1.415 0.228 -1.105 4.556
HOMA-IR 0.037 2.241 0.987 -4.446 4.519
Cholesterol 0.341 0.196 0.088 -0.052 0.734
Triglycerides 0.273 0.093 0.005 0.087 0.458
Leptin 0.527 0.348 0.135 -0.167 1.223
GH 1.643 4.167 0.695 -6.692 9.979
Hypopituitary vs. Control -14.581 18.540 0.435 -51.667 22.505
B: Regression coefﬁcient; SE: Standard Error; CI: Conﬁdence interval
doi:10.1371/journal.pone.0160364.t004
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We found that fasting irisin levels were similar in HP patients and normal subjects. The HP
patients were adequately treated for all pituitary hormone deficits, except for GH, and there
were no significant correlations between irisin and either fasting GH or IGF-I, in this group.
These data suggest that fasting irisin is not regulated by GH in this clinical model. Nevertheless,
we cannot exclude the possibility of GH regulation on irisin in response to acute exercise. In
accordance with our results, it has been found that in abdominally obese men with reduced
GH that neither serum irisin nor the muscle mRNA expression of FNDC5 changed as a result
of exogenous GH treatment [11]. In the HP patients, there were moderate significant positive
correlations between irisin and body fat and HOMA-β. In a number of studies, adiposity
related factors have been found to be an important regulator of irisin. Irisin levels have been
found to be affected by age, sex, obesity, and particularly muscle mass, whereas diurnal rhythm
and meals do not contribute to the variation in children and adults [30]. Irisin strongly reflects
body fat mass, suggesting that circulating irisin levels are conditioned by adiposity level [5].
Circulating irisin levels increase in response to acute exercise, whereas muscle FNDC5 mRNA
and circulating irisin levels decrease after surgically-induced weight loss parallel to a decrease
in body mass [3]. Circulating irisin is positively linked to BMI and leptin in school-age chil-
dren, further supporting again the notion that irisin is produced by adipose tissue [7]. The pos-
sibility of a direct interaction between leptin and irisin has been studied, although leptin
administration does not alter circulating irisin levels in humans [31]. In line with the previous
study, in the HP patients there were no significant correlations between irisin and leptin, sug-
gesting that fasting irisin is not regulated by leptin in this group of patients. Circulating irisin is
affected under conditions of altered BMI with the highest levels in severely obese patients. The
increase of irisin under conditions of obesity may indicate a physiological function to improve
glucose tolerance which is often impaired in obese subjects [26]. Moreover, at tissue level, irisin
has been found to be expressed and produced by human muscle and adipose tissue in associa-
tion with obesity and insulin resistance [32]. The results of our study are in accordance with
the previous studies, and suggest that circulating fasting irisin is highly dependent on direct
and indirect adiposity related markers in both HP and control subjects. Although the determi-
nation of irisin is currently of no clinical relevance in terms of managing hypopituitary
patients, in the near future it could be clinically applicable, as it has the potential to be a marker
of physical exercise, sarcopenia or adiposity in different clinical situations, including
hypopituitarism.
The principal contribution of this work is that, to the best of our knowledge, this is the first
study to measure circulating irisin in HP patients. We evaluated circulating irisin in the pres-
ence of GH deficiency, with both hormones revealing significant metabolic actions. The pres-
ent study has several limitations. The number of patients is relatively small, so its statistical
power is limited. The presence of a certain degree of partial hypogonadism could be another
factor influencing body composition [33]. Moreover, a certain degree of thyroid or adrenal dys-
function cannot be excluded. Nevertheless, the patients were adequately treated for all pituitary
hormone deficits, except for GH, and were on stable hormone replacement therapy for pitui-
tary hormone deficits in the form of levothyroxine, hydrocortisone, desmopressin, and sex ste-
roids for at least 3 months before joining the study. The study was not controlled in terms of
the amount of exercise carried out, although all of the controls and patients were physically
active. None of them were active competitors in sports, and the level of exercise was compara-
ble between controls and HP patients. Moreover, recent data suggest that irisin response to
exercise is mainly transient to acute rather than chronic exercise [30, 34, 35]. Doubts have been
raised about circulating irisin, and there are limitations due to the irisin assay, although recent
data have shown unequivocally that human irisin exists, circulates, and is regulated by exercise
[36].
Irisin in Hypopituitarism
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Conclusions
We found similar irisin levels in GH deficiency hypopituitary patients when compared to nor-
mal subjects. The correlation between irisin and adiposity-related factors suggests that in this
clinical model, irisin is regulated by adiposity and not by GH.
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